Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer February 20, 2018December 14, 2022 Arthur N. Brodsky, PhD
Advances in Personalized Approaches Against Cancer December 22, 2017December 14, 2022 Arthur N. Brodsky, PhD